CDK9/CycT1 degrader-1
CDK9/CycT1 degrader-1 is an autophagy-anchored bifunctional degrader that mediates the degradation of the CDK9/cyclin T1 protein complex. CDK9/CycT1 degrader-1 binds both CDK9 and LC3B simultaneously to form a ternary complex, achieving target protein degradation via the autophagy-lysosome pathway. CDK9/CycT1 degrader-1 downregulates the protein levels of Mcl‑1 and c‑Myc and induces apoptosis. PROTAC CDK9/CycT1 Degrader-2 is applicable to cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 3020773-91-2
- Formula: C30H36N4O6S2
- Molecular Weight:612.76
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CDK9 |
Mcl-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U2932 | IC50 |
45 nM
|
Antiproliferative activity against human U-2932 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
Antiproliferative activity against human U-2932 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay.
|
37671907 |
In Vitro
CDK9/CycT1 degrader-1 (compound 16) inhibits purified CDK9/cycT1 enzyme, with an inhibition rate of 19% at 10 nM and 74% at 100 nM; it also inhibits the proliferation of U-2932 cells, with an IC50 of 45 nM[1].
CDK9/CycT1 degrader-1 (1-1000 nM; 1-24 h) induces dose- and time-dependent degradation of CDK9, and downregulates cyclin T1 and Mcl-1 in U-2932 cells[1].
CDK9/CycT1 degrader-1 (100 nM; 24 h) selectively degrades CDK9 (along with CDK1) in U-2932 cells, while exerting minimal effects on CDK2, CDK4 and CDK7[1].
CDK9/CycT1 degrader-1 (10-1000 nM; 6 h) dose-dependently downregulates pSer2-RNAP2 (with no effect on pSer5-RNAP2) in U-2932 cells[1].
CDK9/CycT1 degrader-1 (10-1000 nM; 6 h) downregulates the mRNA expression of Mcl-1 and c-Myc in a dose-dependent manner in U-2932 cells[1].
CDK9/CycT1 degrader-1 (10-1000 nM; 24 h) induces apoptosis in U-2932 cells[1].
CDK9/CycT1 degrader-1 (500 nM; 12 h, with 2 h pretreatment of 500 nM Bafilomycin A1 or 10 μM Hydroxychloroquine) degrades CDK9 via the autophagy-lysosomal pathway, which is confirmed by the reversed degradation effect in U-2932 cells treated with the autophagy inhibitors Bafilomycin A1 (HY-100558) or Hydroxychloroquine (HY-W031727)[1].
CDK9/CycT1 degrader-1 (500 nM; 12 h, co-treated with 500 nM Bafilomycin A1) promotes the formation of a ternary complex between CDK9 and LC3B in U-2932 cells[1].
CDK9/CycT1 degrader-1 (100 nM; 24 h) mediates CDK9 degradation in an LC3B-dependent manner, as evidenced by the blocked degradation in LC3B-knockout 293T cells compared with wild-type cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U-2932 cells
-
Concentration:100 nM (24 h assessment)
1 nM, 4 nM, 12 nM, 37 nM, 111 nM, 333 nM, 1000 nM (dose-dependent assessment)
100 nM (time-course assessment) -
Incubation Time:24 h (fixed time assessment)
1 h, 3 h, 6 h, 12 h, 24 h (time-course assessment) -
Result:Reduced CDK9 55 and CDK9 42 abundance to 0.70 and 0.41 versus DMSO control after 24 h 100 nM treatment.
Downregulated cyclin T1 and Mcl‑1.
Attained Dmax values of 49.89% (CDK9 42) and 46.02% (CDK9 55) in dose‑dependent assays.
Detected progressive CDK9 depletion commencing at 3 h and continuing to 24 h in time‑dependent assays.
-
Cell Line:U-2932 cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Induced obvious degradation of CDK9.
Showed less effect on CDK2, CDK4, and CDK7.
Induced degradation of CDK1.
-
Cell Line:U-2932 cells
-
Concentration:10 nM, 100 nM, 1000 nM
-
Incubation Time:6 h
-
Result:Dose-dependently downregulated the level of pSer2-RNAP2.
Did not suppress pSer5-RNAP2.
-
Cell Line:U-2932 cells
-
Concentration:10 nM, 1000 nM
-
Incubation Time:6 h
-
Result:Decreased Mcl-1 and c-Myc mRNA levels in a dose-dependent manner.
Reduced Mcl-1 relative expression to near 0 at 1000 nM.
Reduced c-Myc relative expression to near 0 at 1000 nM.
-
Cell Line:U-2932 cells
-
Concentration:10 nM, 100 nM, 1000 nM
-
Incubation Time:24 h
-
Result:Strongly induced apoptosis at 100 nM and 1000 nM.
Achieved an apoptosis rate of 86.1% at 1000 nM.
-
Cell Line:wild-type 293T cells, LC3B-KO 293T cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Induced degradation of CDK9 in wild-type 293T cells.
Blocked CDK9 degradation in LC3B-KO 293T cells.
Parmacokinetics
Chemical Information
-
CAS No. 3020773-91-2
-
Molecular Weight 612.76
-
Formula C30H36N4O6S2
-
SMILES
O=C1OC2=CC(OCCCN3CCC(CC3)C(NC4=NC=C(S4)SCC5=NC=C(O5)C(C)(C)C)=O)=CC(O)=C2C(C)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)